Toward RNA interference-based therapy for filovirus infections

Drug Development Research

Volumn 70, Issue 4, 2009, Pages 246-254

  Spurgers, Kevin B ^a   Silvestri, Lynn S ^a   Warfield, Kelly L ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Ebola; Filovirus; Marburg; RNA interference; siRNA

Indexed keywords

ALN RSV 01; GLYCOPROTEIN; MATRIX PROTEIN; SMALL INTERFERING RNA;

BIOLOGICAL WARFARE; CLINICAL TRIAL; EBOLA VIRUS; FILOVIRUS; GENE FUNCTION; HUMAN; MARBURG VIRUS; NONHUMAN; REVIEW; RNA INTERFERENCE; VIRUS ASSEMBLY; VIRUS HEMORRHAGIC FEVER; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

EID: 67649303068     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20302     Document Type: Review

References (59)

1. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, Fisher-Hoch SP, McCormick JB, Georges AJ. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5:423-426. (Pubitemid 29180581)
2. Bamberg S, Kolesnikova L, Moller P, Klenk HD, Becker S. 2005. VP24 of Marburg virus influences formation of infectious particles. J Virol 79:13421-13433. (Pubitemid 41508155)
3. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297. (Pubitemid 38167318)
4. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, Garcia-Sastre A. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77:7945-7956. (Pubitemid 36792791)
5. Bazhutin NB, Belanov EF, Spiridonov VA, Voitenko AV, Krivenchuk NA, Krotov SA, Omel'chenko NI, Tereshchenko A, Khomichev VV. 1992. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys. Vopr Virusol 37:153-156.
6. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975-990. (Pubitemid 350201788)
7. Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. 2005. The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov 4:281-297. (Pubitemid 41135787)
8. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B. 2004. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 78:2601-2605. (Pubitemid 38228957)
9. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. 2007. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443-453. (Pubitemid 47064567)
10. Elbashir SM, Harborth J, Weber K, Tuschl T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199-213. (Pubitemid 34969582)
11. Emeny JM, Morgan MJ. 1979. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 43:247-252. (Pubitemid 9181666)
12. Falzarano D, Krokhin O, Wahl-Jensen V, Seebach J, Wolf K, Schnittler HJ, Feldmann H. 2006. Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. Chembiochem 7:1605-1611. (Pubitemid 44556008)
13. Feldmann H. 2006. Marburg hemorrhagic fever - the forgotten cousin strikes. N Engl J Med 355:866-869. (Pubitemid 44315978)
14. Feng Z, Cerveny M, Yan Z, He B. 2007. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol 81:182-192. (Pubitemid 44975159)
15. Fowler T, Bamberg S, Moller P, Klenk HD, Meyer TF, Becker S, Rudel T. 2005. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 86:1181-1188. (Pubitemid 40485676)
16. Fritz JH, Girardin SE, Philpott DJ. 2006. Innate immune defense through RNA interference. Sci STKE 2006:pe27.
17. Geary RS, Henry SP, Grillone LR. 2002. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 41:255-260. (Pubitemid 34533756)
18. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. 2003a. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347-2370. (Pubitemid 37466478)
19. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE. 2003b. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163:2371-2382. (Pubitemid 37474154)
20. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR and others. 2006. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193:1650-1657.
21. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541. (Pubitemid 44050158)
22. Gronvall GK, Trent D, Borio L, Brey R, Nagao L. 2007. The FDA animal efficacy rule and biodefense. Nat Biotechnol 25:1084-1087. (Pubitemid 47538099)
23. Groseth A, Feldmann H, Strong JE. 2007a. The ecology of Ebola virus. Trends Microbiol 15:408-416. (Pubitemid 47375107)
24. Groseth A, Hoenen T, Alimonti JB, Zielecki F, Ebihara H, Theriault S, Stroher U, Becker S, Feldmann H. 2007b. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. J Infect Dis 196 (Suppl 2):S382-S389.
25. Haasnoot J, de Vries W, Geutjes EJ, Prins M, de Haan P, Berkhout B. 2007. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3:e86. (Pubitemid 47015879)
26. Hartlieb B, Weissenhorn W. 2006. Filovirus assembly and budding. Virology 344:64-70. (Pubitemid 41814451)
27. Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST. 2008. Inhibition of IRF-3 activation by VP35 is critical for the high virulence of Ebola virus. J Virol 82:2699-2704. (Pubitemid 351329161)
28. Henschel A, Buchholz F, Habermann B. 2004. DEQOR: a web-based tool for the design and quality control of siRNAs. Nucleic Acids Res 32:W113-W120. (Pubitemid 38997311)
29. Hoenen T, Groseth A, Falzarano D, Feldmann H. 2006. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 12:206-215. (Pubitemid 43728410)
30. Huang Y, Xu L, Sun Y, Nabel GJ. 2002. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 10:307-316. (Pubitemid 35007345)
31. Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, Nagley D, Johnson E, Jaax G, Peters C. 1995. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669-1671. (Pubitemid 26003325)
32. Jasenosky LD, Kawaoka Y. 2004. Filovirus budding. Virus Res 106:181-188. (Pubitemid 39572963)
33. John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, Stoffel M, Langer R, Anderson DG, Horton JD, Koteliansky V, Bumcrot D. 2007. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449:745-747. (Pubitemid 47552094)
34. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. 2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39-43. (Pubitemid 47037001)
35. le Sage C, Agami R. 2006. Immense promises for tiny molecules: uncovering miRNA functions. Cell Cycle 5:1415-1421.
36. Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854. (Pubitemid 24014542)
37. Lee SH, Sinko PJ. 2006. siRNA - getting the message out. Eur J Pharm Sci 27:401-410. (Pubitemid 43363336)
38. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415-419. (Pubitemid 37187272)
39. Leffel EK, Reed DS. 2004. Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror 2:186-191.
40. Mahanty S, Bray M. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487-498. (Pubitemid 39077918)
41. Manicassamy B, Wang J, Jiang H, Rong L. 2005. Comprehensive analysis of ebola virus GP1 in viral entry. J Virol 79:4793-4805. (Pubitemid 40464230)
42. Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. 1999. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 73:2333-2342. (Pubitemid 29098138)
43. Muhlberger E. 2007. Filovirus replication and transcription. Future Virol 2:205-215. (Pubitemid 46813445)
44. Orr RM. 2001. Technology evaluation: fomivirsen. Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 3:288-294.
45. Pei Y, Tuschl T. 2006. On the art of identifying effective and specific siRNAs. Nat Methods 3:670-676. (Pubitemid 44275732)
46. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. 2006. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80:5156-5167. (Pubitemid 43752761)
47. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901-906. (Pubitemid 30130993)
48. Shah JK, Garner HR, White MA, Shames DS, Minna JD. 2007. sIR: siRNA Information Resource, a web-based tool for siRNA sequence design and analysis and an open access siRNA database. BMC Bioinformatics 8:178. (Pubitemid 46995455)
49. Sioud M. 2007. RNA interference and innate immunity. Adv Drug Deliv Rev 59:153-163. (Pubitemid 46783844)
50. Sontheimer EJ. 2005. Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol 6:127-138. (Pubitemid 40215808)
51. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. 2008. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 78:26-36.
52. Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, Nabel E, Nabel GJ. 2005. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 79:547-553. (Pubitemid 39648407)
53. Thacker PD. 2003. An Ebola epidemic simmers in Africa: in remote region, outbreak shows staying power. JAMA 290:317-319. (Pubitemid 37430510)
54. Theriault S, Groseth A, Neumann G, Kawaoka Y, Feldmann H. 2004. Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res 106:43-50. (Pubitemid 39441304)
55. Wilson JA, Richardson CD. 2005. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 79:7050-7058. (Pubitemid 40677336)
56. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6:886-889. (Pubitemid 30644746)
57. Ying SY, Chang DC, Miller JD, Lin SL. 2006. The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol Biol 342:1-18.
58. Zampieri CA, Sullivan NJ, Nabel GJ. 2007. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol 8:1159-1164. (Pubitemid 350011751)
59. Zheng ZM, Tang S, Tao M. 2005. Development of resistance to RNAi in mammalian cells. Ann NY Acad Sci 1058:105-118.